<strong>Translational Medicine Study on Circulating Tumor Cell Detection in Patients with Metastatic Breast Cancer </strong>

doi:10.11910/2227-6394.2015.03.02.05

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (359 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To explore the prognostic and predictive effects of circulating tumor cell (CTC) detection in patients with metastatic breast cancer (MBC). Methods: A total of 139 patients with MBC were selected to detect the peripheral blood CTC count by CellSearch system. The survival analysis was conducted according to CTC count, and multivariate Cox regression analysis was performed to analyze the factors influencing the progression-free survival (PFS), so as to diagnose the prognostic and predictive effects of CTC counts on MBC patients. Results: The rates of patients with CTC count ≥5 were 38.85% (54/139), 22.43% (24/107) and 17.27% (19/110) before treatment, 3-4 weeks after treatment and 6-8 weeks after treatment, respectively. Before treatment, the PFS of patients with CTC count ≥5 was evidently lower than those with CTC count <5, which difference was more significant along with time. HR coefficients of CTC to PFS were 1.939, 2.401 and 3.726 before treatment, 3-4 weeks after treatment and 6-8 weeks after treatment, respectively. And CTC was superior to estrogen receptor (ER) or progesterone receptor (PR) condition, human epidermal receptor 2 (HER2) condition and Eastern Cooperative Oncology Group (ECOG) score in the prognostic and predictive values of MBC patients. Conclusion: CTC count can better reflect the therapeutic efficacy, and has higher clinical predictive value in the PFS of MBC patients.

Key words： Breast cancer Circulating tumor cell Translational medicine Prognosis and prediction Progression-free survival

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHEN Bo
	ZHENG Ma-qing
	XU Xin-yu
	WEI Da

Cite this article:

SHEN Bo,ZHENG Ma-qing,XU Xin-yu, et al. Translational Medicine Study on Circulating Tumor Cell Detection in Patients with Metastatic Breast Cancer [J]. Journal of International Translational Medicine, 2015, 3(2): 93-97.

URL:

http://www.jitm.hk/EN/10.11910/2227-6394.2015.03.02.05 OR http://www.jitm.hk/EN/Y2015/V3/I2/93

1 Zhao JW, Qian F. Analysis on Current Status and Plights of Translational Medicine. J Int Transl Med, 2015, 3(1): 59-66.

2 Geraghty J. Adenomatous polyposis coli and translational medicine. Lancet, 1996, 348(9025): 422.

3 Huang XE. Advances in Translational Medicine of Breast Cancer: From Bench to Bedside. J Int Transl Med, 2015, 3(1): 47-52.

4 Xu GH, Li Y, Zhou LN. Bcl-xl Expression and its Relationships with Clinical Pathological Characteristics, Expression of Estrogen and Progestogen Receptors in Breast Cancer. J Int Transl Med, 2014, 2(4): 434-8.

5 Maurie Buehler, Ellie Guardino, Jung Sik Park, et al. Clinical Application of Fluorescence in Situ Hybridization (FISH) to Detect HER-2 Gene in Breast Cancer. J Int Transl Med, 2014, 2(2): 326-30.

6 Li P, Stratton ZS, Dao M, et al. Probing circulating tumor cells in microfluidics. Lab Chip, 2013, 13(4): 602-9.

7 Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett, 2007, 253(2): 180-204.

8 Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem, 2011, 57(9): 1242-55.

9 Parkinson DR, Dracopoli N, Petty BG, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med, 2012, 10: 138.

10 Gazzaniga P, Raimondi C, Gradilone A, et al. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. Ann Oncol, 2011, 22(8): 1929-30.

11 Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer, 2011, 105(6): 847-53.

12 Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst, 2009, 101(1): 61-6.

13 Hong B, Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics, 2013, 3(6): 377-94.

14 Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer, 2011, 105(6): 847-53.

15 Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol, 2012, 7(2): 306-15.

16 Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med, 2010, 16(9): 398-406.

17 Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods, 2010, 50(4): 289-97.

18 De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol, 2009, 27(20): 3303-11.